Apollomics Inc. (Nasdaq: APLM) announced financial results for the first half of 2025, with cash reserves of $2.1 million as of June 30, 2025. R&D expenses were $4.6 million, G&A expenses were $14.5 million, and the net loss for the first half of 2025 was $(12.5) million. The company’s lead program, vebreltinib (APL-101), is in a Phase 2 clinical trial for non-small cell lung cancer.

The financial statements for Apollomics Inc. as of June 30, 2025, show total assets of $11.1 million, with current assets of $10.1 million and non-current assets of $990,000. Current liabilities stand at $10.5 million, resulting in net current liabilities of $(343,000). The company reported a net loss of $(12.5) million for the first half of 2025.

Apollomics Inc. is a late-stage clinical biopharmaceutical company focused on developing oncology drug candidates to address difficult-to-treat cancers. The company’s lead program, vebreltinib, is a c-Met inhibitor currently in a Phase 2 clinical trial. Apollomics cautions investors that forward-looking statements are subject to risks and uncertainties, and they do not guarantee future outcomes. For more information, visit www.apollomicsinc.com.

Read more at GlobeNewswire: Apollomics Reports First Half 2025 Financial Results